当前位置:首页 - 行情中心 - 索宝蛋白(603231) - 财务分析 - 利润表

索宝蛋白

(603231)

  

流通市值:17.60亿  总市值:31.71亿
流通股本:1.06亿   总股本:1.91亿

利润表

报告期2025-03-312024-12-312024-09-302024-06-30
公司类型通用通用通用通用
一、营业总收入391,920,304.591,555,382,604.611,155,092,649.3772,006,015.52
营业收入391,920,304.591,555,382,604.611,155,092,649.3772,006,015.52
二、营业总成本340,412,070.351,435,473,164.941,073,407,161.58709,903,475.59
营业成本323,557,282.91,368,635,123.491,026,920,691.28681,399,841.39
税金及附加1,937,814.317,327,970.745,314,028.723,825,849.49
销售费用5,352,784.4822,919,109.2914,291,897.469,539,464.86
管理费用10,224,417.2938,877,491.626,420,500.4218,162,733.64
研发费用1,405,431.5710,410,192.238,089,606.756,400,049.57
财务费用-2,065,660.2-12,696,722.41-7,629,563.05-9,424,463.36
其中:利息费用61,431.26140,609.19132,091.56127,598.37
其中:利息收入401,664.076,733,649.725,813,425.75,020,348.43
加:公允价值变动收益1,392,917.746,201,917.52,069,361.074,302,516.27
加:投资收益457,457.055,341,043.267,085,298.381,728,241.94
资产处置收益-15,384.63-29,666.6891,590.4291,568.26
资产减值损失(新)--4,052,226.63--
信用减值损失(新)-589,164.594,732,646.14,858,715.284,286,367.94
其他收益733,900.9816,194,450.5314,966,791.5713,551,100.19
营业利润平衡项目0000
四、营业利润53,487,960.79148,297,603.75110,757,244.4486,062,334.53
加:营业外收入176,541.05356,705.75273,986.21161,369.12
减:营业外支出90,732.424,571,806.811,939,049.511,778,125.17
利润总额平衡项目0000
五、利润总额53,573,769.42144,082,502.69109,092,181.1484,445,578.48
减:所得税费用9,097,677.0122,901,768.9417,411,650.0613,647,571.02
六、净利润44,476,092.41121,180,733.7591,680,531.0870,798,007.46
其中:被合并方在合并前实现利润----1,906,750.73
持续经营净利润44,476,092.41121,180,733.7591,680,531.0870,798,007.46
归属于母公司股东的净利润44,476,092.41121,180,733.7591,680,531.0870,798,007.46
(一)基本每股收益0.230.630.480.37
(二)稀释每股收益0.230.630.480.37
八、其他综合收益3,893.03-7,910.06--
归属于母公司股东的其他综合收益3,893.03-7,910.06--
九、综合收益总额44,479,985.44121,172,823.6991,680,531.0870,798,007.46
归属于母公司股东的综合收益总额44,479,985.44121,172,823.6991,680,531.0870,798,007.46
公告日期2025-04-252025-04-252024-10-262024-08-30
审计意见(境内)标准无保留意见
TOP↑